TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $49.00 at HC Wainwright

TG Therapeutics (NASDAQ:TGTX) had its target price hoisted by research analysts at HC Wainwright from $45.00 to $49.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 197.33% from the company’s current price.

Other equities analysts have also issued research reports about the company. The Goldman Sachs Group lifted their price target on TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a research note on Thursday, April 18th. B. Riley lifted their target price on TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Monday, February 5th. StockNews.com lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. Finally, LADENBURG THALM/SH SH raised their price target on TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.83.

TG Therapeutics Trading Up 3.8 %

NASDAQ:TGTX traded up $0.60 during trading hours on Thursday, hitting $16.48. The company had a trading volume of 5,505,875 shares, compared to its average volume of 4,296,978. The company has a market capitalization of $2.55 billion, a PE ratio of 828.91 and a beta of 2.33. The stock has a 50-day moving average price of $15.13 and a 200 day moving average price of $14.33. TG Therapeutics has a 52 week low of $6.46 and a 52 week high of $35.67. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $63.47 million for the quarter, compared to analysts’ expectations of $54.60 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The business’s quarterly revenue was up 713.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.28) EPS. On average, equities research analysts predict that TG Therapeutics will post -0.11 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the sale, the director now directly owns 215,229 shares in the company, valued at $3,437,207.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 9.20% of the company’s stock.

Institutional Trading of TG Therapeutics

Several large investors have recently made changes to their positions in TGTX. Commonwealth Equity Services LLC increased its position in shares of TG Therapeutics by 19.6% during the third quarter. Commonwealth Equity Services LLC now owns 182,400 shares of the biopharmaceutical company’s stock worth $1,525,000 after purchasing an additional 29,878 shares in the last quarter. Raymond James & Associates lifted its position in TG Therapeutics by 2.9% during the 3rd quarter. Raymond James & Associates now owns 150,190 shares of the biopharmaceutical company’s stock worth $1,256,000 after acquiring an additional 4,176 shares in the last quarter. Stratos Wealth Partners LTD. acquired a new position in TG Therapeutics during the 3rd quarter worth approximately $87,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in TG Therapeutics by 11.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,412 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 2,805 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in TG Therapeutics by 25.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 85,580 shares of the biopharmaceutical company’s stock worth $715,000 after acquiring an additional 17,207 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.